Inflammatory diseases in the Veteran population arise in many ways, ranging from infections, especially of wounds, to metabolic disorders aggravated by stress from tours of duty. Their sequelae range from acute, life-threatening microbial inflammation to chronic and debilitating metabolic inflammation. The body's response to microbial (bacteria, fungi, viruses) and metabolic (excess cholesterol, triglycerides, uric acid) insults is mediated by innate immunity and inflammation. Whatever the source of the stimulus, the response is at first beneficial, but can soon induce harmful inflammatory and metabolic changes in multiple organs. The common nexus of innate immune responses to microbial and metabolic stimuli is intracellular signaling to the nucleus, where the genome is reprogrammed to perpetuate inflammation. However, the interrelation of inflammatory and metabolic signaling in development of disease is poorly understood. We have developed nuclear transport modifiers (NTMs), cell-penetrating peptides designed to inhibit the intracellular nuclear adaptor proteins known as importin alpha 5 (Imp ?5) and importin beta 1 (Imp ?1) from shuttling both inflammatory and lipid-controlling signals, respectively, to the nucleus. NTMs reduce inflammation by targeting Imp ?5-mediated nuclear transport of Stress-Responsive Transcription Factors (SRTFs), exemplified by nuclear factor kappa B, the master regulator of inflammation and immunity. NTMs also inhibit Imp ?1-mediated nuclear transport of Sterol Regulatory Element-Binding Protein (SREBP) transcription factors, the master regulators of cholesterol, triglyceride, and fatty acid syntheses and uptake. NTMs have been effective in ameliorating the inflammatory process in relevant preclinical models of microbial, autoimmune, and metabolic diseases. We hypothesize that microbial inflammation is dependent mainly on the Imp ?5 pathway whereas metabolic inflammation requires both Imp ?5- and Imp ?1-mediated pathways. We further hypothesize that cross-talk between the SRTF/Imp ?5 and SREBP/Imp ?1 signaling pathways predisposes individuals with excessive fat to be more susceptible to microbial insults. We will apply newly designed and produced NTMs as unique probes to independently target Imp ?5 or Imp ?1 and analyze the two pathways they mediate. We will employ cell-based assays and preclinical models of inflammation induced by a potent proinflammatory microbial virulence factor, bacterial endotoxin, or by a High Fat Diet in atherosclerosis-prone mouse strains. With these unique probes already in hand, Aim 1 will define the role of these two distinct nuclear transport signaling pathways in microbial inflammation, while Aim 2 will define their role in metabolic inflammation.
Aim 3 will analyze the comparative roles of SRTF/Imp ?5 and SREBP/Imp ?1 signaling pathways in development of hypersensitivity to endotoxin in individuals with excessive fat. Cumulatively, our mechanistic studies of nuclear transport will yield much-needed information about innate immune responses to microbial and metabolic insults that are regulated by SRTFs and SREBPs.
The majority of acute and chronic diseases afflicting Veterans are mediated by inflammation exacerbated by metabolic changes. This study will use unique tools generated in our laboratory to gain new knowledge about the mechanism and control of these inflammatory responses to microbes and fats and their potential connections. The insights gleaned from these studies will be critical for the development of more effective methods for the prevention and treatment of acute and chronic diseases caused by microbes and excessive fat.
|Veach, Ruth Ann; Liu, Yan; Zienkiewicz, Jozef et al. (2017) Survival, bacterial clearance and thrombocytopenia are improved in polymicrobial sepsis by targeting nuclear transport shuttles. PLoS One 12:e0179468|
|Wylezinski, Lukasz S; Hawiger, Jacek (2016) Interleukin 2 Activates Brain Microvascular Endothelial Cells Resulting in Destabilization of Adherens Junctions. J Biol Chem 291:22913-22923|
|Wynn, James Lawrence; Wilson, Chris S; Hawiger, Jacek et al. (2016) Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proc Natl Acad Sci U S A 113:E2627-35|